• search

Zydus Cadila files IND application for NME-ZYH2

Written by: Staff

Mumbai, Mar 27 (UNI) With continued success in its research programme, Zydus Cadila has filed another investigational new drug application for New Molecular Entity (NME)- ZYH2 with the Drug Controller General of India (DCGI).

A press release issued here today stated that this novel agent for treating diabetes has been designed and developed by Zydus Research Centre, the research wing of Zydus Cadila.

'ZYH2' has displayed a unique profile in pre-clinical studies, stated the release, adding that the NME has the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia.

It also works favourably to lower the elevated lipid levels.

In recent times, glitazones (rosiglitazone and pioglitazone) have been launched to treat increasing prevalence of insulin resistance in Type-II diabetes.

The pre-clinical studies on ZYH2 indicate that this NME may be more effective for diabetics by improving insulin resistance and lowering blood glucose levels without causing hypoglycemia and in also controlling the elevated tryglycerides level which is commonly found in such patients and may require specific intervention.

NME Research is one of the three focus areas of Zydus Research Programme. Under this, the focus has been on metabolic disorders, which includes dyslipidemia, diabetes and obesity and Inflammatory disorders.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more